1-Phenyl-2-Pyridinyl Alkyl Alcohol Derivatives for Selective PDE4 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PDE4 inhibitors, such as rolipram and roflumilast, suffer from undesirable side effects due to their action on high affinity binding sites in the central nervous system and parietal cells, limiting their therapeutic efficacy and safety profile, especially for respiratory diseases like asthma and COPD.
Innovation Solution
Development of derivatives of 1-phenyl-2-pyridinyl alkyl alcohols with specific structural formulas that act as inhibitors of the phosphodiesterase 4 (PDE4) enzyme, targeting the low affinity binding site (LPDE4) to reduce systemic exposure and side effects, while maintaining therapeutic effectiveness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PDE4 inhibitors with high affinity for HPDE4 are used, then strong anti-inflammatory effect is achieved, but side effects such as nausea, emesis and gastric acid secretion increase
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (substituents at positions 3 and 5 of the pyridine ring, specific R1-R6 groups) that create selective affinity for LPDE4 over HPDE4. This localized molecular design ensures the drug acts preferentially on the target enzyme form in inflammatory cells while sparing other PDE4 forms in the CNS and gastric cells.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters (substituent types, positions, and configurations) to optimize the affinity ratio between LPDE4 and HPDE4. The specified structural parameters (R1-R6 groups, aromatic ring substitutions) are tuned to achieve the desired selectivity profile, transforming a non-selective inhibitor into a selective LPDE4 inhibitor.
2Reliability
If systemic administration of PDE4 inhibitors is used, then therapeutic effect is achieved, but systemic exposure increases leading to side effects
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (substituents at positions 3 and 5 of the pyridine ring, specific R1-R6 groups) that create selective affinity for LPDE4 over HPDE4. This localized molecular design ensures the drug acts preferentially on the target enzyme form in inflammatory cells while sparing other PDE4 forms in the CNS and gastric cells.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters (substituent types, positions, and configurations) to optimize the affinity ratio between LPDE4 and HPDE4. The specified structural parameters (R1-R6 groups, aromatic ring substitutions) are tuned to achieve the desired selectivity profile, transforming a non-selective inhibitor into a selective LPDE4 inhibitor.
3Reliability
If first-generation PDE4 inhibitors (rolipram, piclamilast) are used, then PDE4 inhibition is achieved, but selectivity for LPDE4 is insufficient causing undesirable side effects
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (substituents at positions 3 and 5 of the pyridine ring, specific R1-R6 groups) that create selective affinity for LPDE4 over HPDE4. This localized molecular design ensures the drug acts preferentially on the target enzyme form in inflammatory cells while sparing other PDE4 forms in the CNS and gastric cells.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters (substituent types, positions, and configurations) to optimize the affinity ratio between LPDE4 and HPDE4. The specified structural parameters (R1-R6 groups, aromatic ring substitutions) are tuned to achieve the desired selectivity profile, transforming a non-selective inhibitor into a selective LPDE4 inhibitor.
Data Source
AI summary
The invention relates to inhibitors of the phosphodiesterase 4 (PDE4) enzyme. More particularly, the invention relates to compounds that are derivatives of 1-phenyl-2-pyridinyl alkyl alcohols, methods of preparing such compounds, compositions containing them and therapeutic use thereof.